特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
762890

世界の免疫療法市場調査と予測

Global Immunotherapy Market Research and Forecast, 2018-2023

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
世界の免疫療法市場調査と予測
出版日: 2018年11月09日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の免疫療法市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査サマリー

第2章 市場概要と考察

  • 定義
  • アナリストの考察と現在の市場動向
    • 主な調査結果
    • 提言
    • 結論
  • 法規制

第3章 市場決定因子

  • 促進因子
  • 阻害因子
  • 機会

第4章 市場セグメンテーション

  • タイプ別市場
    • モノクローナル抗体
    • 癌ワクチン
    • 自己免疫チェックポイント阻害剤
    • インターロイキンとインターフェロン
    • カルメットゲラン菌
    • 適応的細胞治療
    • その他
  • 用途別市場
    • 自己免疫疾患と炎症性疾患
    • 感染症
    • その他
  • エンドユーザー別市場
    • 病院・クリニック
    • 診断センター
    • その他

第5章 競合環境

  • 主な戦略分析
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業のプロファイル

図表

List of Tables

  • TABLE # 1 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 2 GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 3 GLOBAL CANCER VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 4 GLOBAL AUTOIMMUNE CHECKPOINT INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 5 GLOBAL INTERFERON AND INTERLEUKINS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 6 GLOBAL BACILLUS CALMETTE-GUERIN (BCG) MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 7 GLOBAL ADOPTIVE CELL THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 8 GLOBAL OTHER NON-SPECIFIC IMMUNOTHERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 9 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 10 GLOBAL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 11 GLOBAL AUTOIMMUNE AND INFLAMMATORY DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 12 GLOBAL INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 13 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 14 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 15 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 16 GLOBAL DIAGNOSTIC CENTRES MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 17 GLOBAL OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2017-2023 ($ MILLION)
  • TABLE # 18 GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2017-2023 ($ MILLION)
  • TABLE # 19 NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 20 NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 21 NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 22 NORTH AMERICAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 23 EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 24 EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 25 EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 26 EUROPEAN IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 27 ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
  • TABLE # 28 ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 29 ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 30 ASIA-PACIFIC IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)
  • TABLE # 31 REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY TYPE, 2017-2023 ($ MILLION)
  • TABLE # 32 REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 33 REST OF THE WORLD IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY END-USER, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL IMMUNOTHERAPY MARKET SHARE BY TYPE, 2017 AND 2023 (%)
  • FIGURE # 2 GLOBAL IMMUNOTHERAPY MARKET SHARE BY APPLICATION, 2017 AND 2023 (%)
  • FIGURE # 3 GLOBAL IMMUNOTHERAPY MARKET SHARE BY END-USER, 2017 AND 2023 (%)
  • FIGURE # 4 GLOBAL IMMUNOTHERAPY MARKET SHARE BY GEOGRAPHY, 2017-AND 2023 (%)
  • FIGURE # 5 US IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 CANADA IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 UK IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 FRANCE IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 GERMANY IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 ITALY IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 SPAIN IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 ROE IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 INDIA IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 CHINA IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 JAPAN IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 17 REST OF ASIA-PACIFIC IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 18 REST OF THE WORLD IMMUNOTHERAPY MARKET SIZE, 2017-2023 ($ MILLION)
目次
Product Code: OMR2018414

Immunotherapy is a way of treatment that boosts the body's natural defense to fight cancer and other diseases. Immunotherapy has proven to be an effective way for the treatment of cancer as it has better chances of successfully fighting cancer and protect patients from the disease for a longer period.

Increasing demand for targeted therapies over traditional therapies is augmenting the need for immunotherapy globally. Drugs such as Thalidomide, Lenalidomide, and Pomalidomide, were the treatment options available in the last few years. Introduction of immunomodulatory drugs, such as monoclonal antibodies and HDCA inhibitors, designed to target receptors for myeloma, is expected to initiate newer trends in the market. Cancer immunotherapies is widely being adopted due to the drawbacks associated with chemotherapy such as organ failure, recurrence of cancer and other side effects. Increasing support by various governments to develop cancer immunotherapies will benefit in the growth of this market. After the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia has fuelled the development of monoclonal antibodies as effective immunotherapeutic options. Increasing investments in R&D pertaining to the use of monoclonal bodies as naked antigen-binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have resulted in the discovery of new therapeutic options for cancer treatment.

However, the high cost of this drugs and stringent regulatory policies in some regions are restraining market growth. The market for immunotherapy will show significant growth in near future owing to the introduction of new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy that are in the pipeline and being evaluated for their effectiveness in treating cancer. Additionally, increase in a number of approvals for new immunotherapeutic drugs such as Opdivo, Keytruda, and Tecentriq approved for lung tumors are augmenting the growth of the market and are prescribed in cases of reoccurrence of tumor post-chemotherapy.

The immunotherapy market is segmented on the basis of type, application, and end-user. On the basis of type, the market is bifurcated into monoclonal antibodies, cancer vaccines, autoimmune checkpoint inhibitors, interleukins and interferon (cytokinins), Bacillus Calmette-Guerin (BCG), adoptive cell therapy and other non-specific immunotherapies. Monoclonal antibodies are one of the significant markets owing to the rising investments on R&D of monoclonal antibodies. Monoclonal antibodies for cancer treatment have opened new opportunities for revenue generation for companies that provide oncology therapeutics. Checkpoint inhibitors are used as an initial treatment in patients suffering from an advanced lung tumor. On the basis of end-user, the market is divided into hospitals and clinics, diagnostic centers and others.

The global immunotherapy market is studied on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America is dominating the market for immunotherapy owing to the high penetration of the drugs in the market and greater adoption of immunotherapy drugs due to the high prevalence of cancer. Additionally, factors such as the high affordability of therapies due to the presence of well-structured reimbursement plans are the factors for the preferable market growth in this region. Europe is the second largest market for immunotherapy drugs owing to the greater expenditure on healthcare and the presence of pharmaceutical companies in the region. Asia-Pacific is the fastest growing market for immunotherapy drugs due to the increasing adoption of newer forms of therapy for cancer treatment.

The companies contributing to the growth of global immunotherapy market are Advaxis, Inc., AbbVie, Inc., AstraZeneca PLC, Adaptimmune Therapeutics PLC, Aduro Biotech, Inc., Bristol Myer Squibb and Company, Ziopharm Oncology Inc. and so on. In August 2017, US regulators approved a drug made by Novartis and marketed as Kymriah, the first cancer drug that uses a patient's own cells to fight cancer. It is a super expensive and is priced at $475,000. Kymriah is an intravenous treatment patient to treat acute lymphocytic leukemia, the most common type of childhood cancer in the US.

Research methodology

The market study of the global immunotherapy market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • An authentic database such as the Immunotherapy Foundation, American Cancer Society and so on.
  • Company websites and their product/ services catalog.

The report is intended for biotechnology and life science companies, research institutes and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, growth opportunity in the market and product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

THE REPORT COVERS

  • Comprehensive research methodology of global immunotherapy market.
  • This report also includes a detailed and extensive market overview with analyst insights & key market trends.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global immunotherapy market.
  • Insights about market determinants which are stimulating the global immunotherapy market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Broad profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Definition
  • 2.2. Analyst Insights & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendation
    • 2.2.3. Conclusion
  • 2.3. Regulations
    • 2.3.1. United States
    • 2.3.2. European Union
    • 2.3.3. China
    • 2.3.4. India
    • 2.3.5. Rest of The World

3. Market Determinant

  • 3.1. Motivators
    • 3.1.1. Increasing Adoption of Targeted Therapy Over Traditional Therapy
    • 3.1.2. Rise of Auto-Immune Diseases Among Adults
    • 3.1.3. Increasing Investment in Cancer Research and Funding
    • 3.1.4. Rise in Monoclonal Body Production for Cancer Treatment
    • 3.1.5. Increasing Approvals for Immunotherapies
  • 3.2. Restraints
    • 3.2.1. High Cost Of Cancer Immunotherapies
    • 3.2.2. Stringent Regulatory Policies in Some Regions
  • 3.3. Opportunities
    • 3.3.1. Growing Market in Emerging Economies Such as China and India
    • 3.3.2. Pipeline Products From Key Players to Boost the Immunotherapy Market
    • 3.3.3. Increasing Healthcare Expenditure

4. Market Segmentation

  • 4.1. Global Immunotherapy Market by Type
    • 4.1.1. Monoclonal Antibodies
    • 4.1.2. Cancer Vaccines
    • 4.1.3. Autoimmune Checkpoint Inhibitors
    • 4.1.4. Interleukins And Interferons ( Cytokinins)
    • 4.1.5. Bacillus Calmette-Guerin (BCG)
    • 4.1.6. Adoptive Cell Therapy
    • 4.1.7. Other Non-Specific Immunotherapies
  • 4.2. Global Immunotherapy Market by Application
    • 4.2.1. Cancer
    • 4.2.2. Autoimmune and Inflammatory Diseases
    • 4.2.3. Infectious Diseases
    • 4.2.4. Other
  • 4.3. Global Immunotherapy Drugs Market by End-User
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centres
    • 4.3.3. Others

4.3.4.Competitive Landscape

    • 4.3.5. Key Company Analysis
    • 4.3.6. Key Strategy Analysis

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. United Kingdom
    • 5.2.2. France
    • 5.2.3. Germany
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of The World

6. Company Profiles

  • 6.1. Advaxis, Inc.
  • 6.2. AbbVie, Inc.
  • 6.3. AstraZeneca PLC
  • 6.4. Adaptimmune Therapeutics PLC
  • 6.5. Aduro Biotech, Inc.
  • 6.6. Agenus, Inc.
  • 6.7. Atara Biotherapeutics, Inc.
  • 6.8. Bellicum Pharmaceuticals, Inc.
  • 6.9. Bristol Myer Squibb, Co.
  • 6.10. Bluebird Bio, Inc.
  • 6.11. Celldex Therapeutics, Inc.
  • 6.12. CytomX Therapeutics
  • 6.13. Gilead Science Inc.
  • 6.14. Incyte Corporation
  • 6.15. Johnson & Johnson, Inc.
  • 6.16. Juno Therapeutics, Inc.
  • 6.17. Jounce Therapeutics, Inc.
  • 6.18. Novartis International AG
  • 6.19. Merck & Co., Inc.
  • 6.20. Xencor, Inc.
  • 6.21. MacroGenics, Inc.
  • 6.22. ZIOPHARM Oncology Inc.
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.